Hepatitis C virus (HCV) infections represent a major worldwide health problem with an estimated 0.5-1.5% of the population infected. Approximately 70% of infected individuals develop chronic infections that may lead to cirrhosis and hepatocellular carcinoma. The introduction of diagnostic assays for antibodies to HCV has reduced the risk of transfusion associated HCV, but will have little impact on the spread of the disease by other routes. The development of efficacious antiviral treatments for this agent are essential to control the spread of the disease. A greater understanding of the replicative mechanisms of the virus will be essential in the development of antiviral therapies. A critical need exists for model systems to study replicative functions of the virus as well as tissue culture systems permissive for HCV replication. This proposal directly addresses these needs.
The specific aims are 1) to construct full length clones of HCV and evaluate the clones for infectivity in a variety of cell culture systems; 2) to adapt HCV for replication in continuous cell lines by co- cultivation of cell lines with HCV-infected primary hepatocytes; and 3) to define the 3' HCV sequences required in cis for negative strand RNA replication. An additional aim is 4) to evaluate HCV-infected chimpanzees for the presence of antibody negative viral carriers and for the antibody response to native envelope proteins. The long term goals are to develop a better understanding at a molecular level of HCV replication. The model systems developed for these studies will be of great value in the evaluation of antiviral agents and will provide new targets for the development of antivirals. Accomplishments of the goals of this proposal will significantly impact the likelihood of developing efficacious treatments for this disease.

Project Start
1999-08-01
Project End
2000-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Type
DUNS #
041367053
City
Galveston
State
TX
Country
United States
Zip Code
77555
Jarret, Abigail; McFarland, Adelle P; Horner, Stacy M et al. (2016) Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. Nat Med 22:1475-1481
Hong, MeeAe; Schwerk, Johannes; Lim, Chrissie et al. (2016) Interferon lambda 4 expression is suppressed by the host during viral infection. J Exp Med 213:2539-2552
Yi, MinKyung; Hu, Fengyu; Joyce, Michael et al. (2014) Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee. J Virol 88:3678-94
Wilkins, Courtney; Woodward, Jessica; Lau, Daryl T-Y et al. (2013) IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 57:461-9
Li, Kui; Lemon, Stanley M (2013) Innate immune responses in hepatitis C virus infection. Semin Immunopathol 35:53-72
Horner, Stacy M; Park, Hae Soo; Gale Jr, Michael (2012) Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix ?0. J Virol 86:3112-20
Welsch, Christoph; Schweizer, Sabine; Shimakami, Tetsuro et al. (2012) Ketoamide resistance and hepatitis C virus fitness in val55 variants of the NS3 serine protease. Antimicrob Agents Chemother 56:1907-15
Zhou, Yan; Callendret, BenoƮt; Xu, Dan et al. (2012) Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection. J Exp Med 209:1481-92
Grebely, Jason; Prins, Maria; Hellard, Margaret et al. (2012) Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 12:408-14
Shimakami, Tetsuro; Yamane, Daisuke; Jangra, Rohit K et al. (2012) Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci U S A 109:941-6

Showing the most recent 10 out of 156 publications